🇺🇸 FDA
Pipeline program

Selinexor

MCC-18630

Phase 3 small_molecule active

Quick answer

Selinexor for Multiple Myeloma is a Phase 3 program (small_molecule) at Karyopharm Therapeutics with 12 ClinicalTrials.gov record(s).

Program details

Company
Karyopharm Therapeutics
Indication
Multiple Myeloma
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials